Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;69(2):246-50.
doi: 10.1001/archneurol.2011.732.

Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort

Abhay Moghekar  1 , Joshua Goh, Ming Li, Marilyn Albert, Richard J O'Brien
Affiliations

Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort

Abhay Moghekar et al. Arch Neurol. 2012 Feb.

Abstract

Objective: To determine whether cerebrospinal fluid (CSF) biomarkers for Alzheimer disease fluctuate significantly over time in a cohort of older, mildly symptomatic individuals.

Design: Biomarker validation in a clinical cohort.

Setting: University hospital inpatient unit.

Participants: Ten patients admitted for CSF drainage for diagnostic purposes.

Main outcome measures: The CSF levels of Aβ1-40, Aβ1-42, tau, and phosphorylated tau on threonine 181 (p-tau(181)) were measured every 6 hours for 24 or 36 hours.

Results: The mean coefficient of variation values for each biomarker assessed in our 10 patients were 5.5% (95% CI, 3.8%-10.0%) for Aβ1-42, 12.2% (9.0%-24.2%) for Aβ1-40, 8.2% (5.7%-15.1%) for total tau, and 11.9% (8.5%-23.0%) for p-tau(181). These values are only slightly higher than the variability in the assay. In addition, no significant circadian fluctuation in any Alzheimer disease biomarker was observed given the limitations of our sampling frequency.

Conclusion: In a cohort of elderly patients, little fluctuation in the levels of important Alzheimer disease biomarkers in lumbar CSF is seen as a function of time.

PubMed Disclaimer

Figures

Figure
Figure
Temporal fluctuations of cerebrospinal fluid (CSF) Aβ1–42, Aβ1–40, tau, and phosphorylated tau on threonine 181 (p-tau181). The CSF levels of each of the 4 biomarkers were determined in specimens collected 6 hours apart, starting at 6 pm. Each point represents the mean of each sample run in triplicate. Data on individual patients are color coded.
See this image and copyright information in PMC

References

    1. Green RC, Schneider LS, Amato DA, et al. Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557–2564. - PMC - PubMed
    1. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216–223. - PubMed
    1. McGuinness B, O’Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2010;(8):CD007514. - PubMed
    1. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43(8):1467–1472. - PubMed
    1. Clark CM, Schneider JA, Bedell BJ, et al. AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology [published correction appears in JAMA. 2011;305(11):1096] JAMA. 2011;305(3):275–283. - PMC - PubMed

Publication types